Levatrop (Levosimendan)

Levosimendan is used in the management of acute heart failure syndromes, where it enhances cardiac performance.

• Acute decompensated heart failure: improves cardiac output and relieves pulmonary congestion.
• Severe chronic heart failure (adjunctive therapy): provides temporary hemodynamic support during exacerbations.
• Low cardiac output syndrome after cardiac surgery: enhances myocardial contractility and facilitates weaning from mechanical support.

• Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby augmenting myocardial contractility without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous dilation. The combined inotropic and vasodilatory actions lower cardiac preload and afterload, improving overall cardiac efficiency.

Levosimendan may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache
• Nausea
• Vomiting
• Hypotension
• Tachycardia
• Flushing

Serious or Rare Side Effects

• Arrhythmias (including ventricular tachycardia)
• Myocardial ischemia
• Severe hypotension requiring intervention
• Allergic reactions (anaphylaxis, rash)
• Electrolyte disturbances (e.g., hyperkalemia)

When using Levatrop, clinicians should observe specific safety measures to minimize risk.

• Patient selection: assess for severe hypotension or obstructive cardiac lesions before initiation.
• Monitoring: continuously monitor blood pressure, heart rate, and ECG during infusion.
• Renal function: adjust therapy in patients with impaired renal clearance.
• Hepatic function: use caution in severe liver disease due to altered metabolism.
• Concomitant vasodilators: avoid concurrent high‑dose nitrates or phosphodiesterase‑5 inhibitors to prevent excessive hypotension.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations.
• Concurrent use with other inotropes (e.g., dopamine, dobutamine) at high doses: risk of excessive cardiac stimulation.
• Nitrates or phosphodiesterase‑5 inhibitors: can cause profound hypotension.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate hypotensive effects; monitor fluid status.
• Anticoagulants (e.g., warfarin): monitor INR as hemodynamic changes can affect coagulation.
• Beta‑blockers: may blunt desired inotropic response; adjust dosing as needed.